Interestingly, the novel cannabinoid receptor-1 (CB1R) inverse agonist, INV-202/monlunabant in subjects with metabolic syndrome causes a remarkable reduction in body weight and improvement in the cardiometabolic profile without adverse effects [72]. Here, CNR1 is linked to metabolic syndrome.